- Home
- CTO vs OMER Comparison
CTO vs OMER Comparison
Compare CTO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | OMER |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.3M | 844.6M |
| IPO Year | 1995 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CTO | OMER |
|---|---|---|
| Price | $20.31 | $20.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $22.50 | ★ $32.50 |
| AVG Volume (30 Days) | 299.5K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | ★ 122.86 | 98.15 |
| EPS | 0.13 | ★ 0.77 |
| Revenue | ★ $149,545,000.00 | $29,868,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | $233.22 |
| P/E Ratio | $156.77 | ★ $27.34 |
| Revenue Growth | ★ 20.10 | N/A |
| 52 Week Low | $15.07 | $4.06 |
| 52 Week High | $22.71 | $21.24 |
Technical Indicators
Market Signals| Indicator | CTO | OMER |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 67.82 |
| Support Level | N/A | $18.00 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.82 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 89.35 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.